loading

Perché le azioni Aclaris Therapeutics Inc (ACRS) sono in ribasso?

Abbiamo notato un calo di 5.08% nelle azioni di Aclaris Therapeutics Inc (ACRS) durante la sessione di negoziazione di 2025-04-15. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
diagnostics_research LH
$247.66
price up icon 2.64%
diagnostics_research DGX
$177.95
price up icon 0.36%
diagnostics_research WAT
$350.45
price up icon 2.52%
$156.66
price up icon 3.50%
diagnostics_research MTD
$1,100.01
price up icon 4.11%
diagnostics_research IQV
$153.48
price up icon 1.58%
Capitalizzazione:     |  Volume (24 ore):